Xiangyu Medical Co. Ltd. A688626
▲ PositiveTechnologyrelevance
Xiangyu Medical leads consortium expansion, establishes joint lab, signs clinical agreements, and showcases BCI products, driving innovation.
Impact on stocks 1
Others▲ · 1 stocks
Xiangyu Medical Co. Ltd. ATheme Impact 1
Off-coverage companies
Related news
▲
MIIT outlines action path for AI plus manufacturing; China Southern Fund positions in related industries
At a State Council Information Office press conference on the 15th Five-Year Plan, the Ministry of Industry and Information Technology said it will stay application-driven, deepen the implementation of AI plus manufacturing, support research and development of key technologies such as high-end training chips and multimodal algorithms, tackle frontier technologies including brain-inspired intelligence and world models, advance the iteration of intelligent terminals such as humanoid robots and brain-computer interfaces, and distill high-value scenarios by industry while rolling out a batch of lightweight, low-cost, easy-to-deploy industry solutions. Multiple products under China Southern Fund are positioned in the artificial intelligence industry, including China Southern Digital Economy Mixed Fund, China Southern Technology Pilot Mixed Fund, China Southern Yihe Flexible Allocation Mixed Fund, China Southern Emerging Leaders Flexible Allocation Mixed Fund, and China Southern China Dream Flexible Allocation Mixed Fund.
▲
MIIT Releases Brain-Computer Interface Standards Guidelines; Over 30 Listed Companies Have Layouts
The Ministry of Industry and Information Technology released on August 24 a draft for comments of the National Brain-Computer Interface Industry Standards System Construction Guidelines 2026 Edition, proposing to formulate or revise more than 40 standards in the brain-computer interface field by 2028 and to promote standards publicity and implementation among over 100 enterprises. In early trading today, consumer sector indices such as daily chemicals, tourism, and hotels and catering led gains, with the daily chemicals industry rising the most. Proya, Betaini, and SYoung Group all gained more than 5 percent, while Qingdao Kingking shot up and sealed the daily limit within two minutes, becoming the only limit-up stock in the daily chemicals sector. Brain-computer interface concept stocks have fallen an average of 15.74 percent this year, but since August the average daily turnover of 10 concept stocks has increased month on month. Beijing Beilu Pharmaceutical had an average daily turnover of 317 million yuan, up 71.83 percent month on month, ranking first. According to statistics from Securities Times Data Treasure, there are currently more than 30 A-share concept stocks involved in the brain-computer interface industry chain, with companies such as Medlander, Vishee, Meihao Medical, Apon Medical, and ZKTeco all having layouts.
10
New Journey plans to acquire 51% of Shandong Zepu for 437 million yuan, with a premium rate exceeding 600%
New Journey announced plans to acquire a 51% stake in Shandong Zepu Medical Technology for 437 million yuan, with the transaction premium rate reaching 615.30%. As of the valuation base date, Shandong Zepu's net asset book value was 77.1475 million yuan, while the income approach valuation reached as high as 552 million yuan. Its technology portfolio spans hot sectors including AI, embodied intelligence, brain-computer interfaces, and rehabilitation robots. Shandong Zepu posted a net loss of 6.4816 million yuan in 2024, turned profitable in 2025 with net profit of 23.4642 million yuan, and recorded net profit of 7.6776 million yuan in the first four months of this year. New Journey's net profit attributable to the parent company fell 73.04% year-on-year to 30.9428 million yuan in 2025, with an asset-liability ratio of 69.73%. The acquisition price will be funded entirely from its own and self-raised funds, and is expected to generate goodwill of approximately 210 million to 240 million yuan.